You just read:

Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer

News provided by

Astellas Pharma Inc.

Jun 09, 2017, 08:00 ET